• Tomo Ando, Hisato Takagi, and Cindy L Grines.
• Harper Hospital/Detroit Medical Center, Division of Cardiology, Wayne State University, Detroit, Michigan.
• J Interv Cardiol. 2017 Aug 1; 30 (4): 309-317.

ObjectivesTo determine whether drug-eluting stent (DES) coronary complete revascularization (CR) confers clinical benefit over incomplete revascularization (IR) in patients with multivessel coronary artery disease (MVD).BackgroundClinical benefit of CR over IR in patients with MVD with angina (both stable and unstable) and non-ST-segment elevation myocardial infarction (NSTEMI) in DES has not been well studied.MethodsWe conducted a systematic online literature search of PUBMED and EMBASE. Literatures that compared the clinical outcomes between CR and IR with exclusively or majority (>80%) using DES in patients without or included only small portion (<20%) of ST-segment elevation myocardial infarction or single-vessel coronary artery disease were included. Hazards ratio (HR) with 95% confidence interval (CI) was calculated with random-effects model.ResultsNo randomized clinical trials were identified. A total of 14 observational studies with total of 41 687 patients (CR 39.6% and IR 60.4%) were included in this meta-analysis. CR was associated with lower incident of all-cause mortality (HR 0.71, P = 0.001), major adverse events (HR 0.75, P < 0.001), cardiovascular mortality (HR 0.39, P < 0.001). Meta-regression analysis showed that CR significantly reduced the risk of all-cause mortality in advanced age, triple vessel disease and male sub-groups.ConclusionsCR with DES conferred favorable outcomes compared to IR in MVD patients with stable, unstable angina or NTEMI. Further research to achieve higher CR in MVD patients may lead to improvement in prognosis in these cohorts.© 2017, Wiley Periodicals, Inc.

20 keywords...

hide…